COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 14th April 2020. As a result, our offices will now be closed till 14th April 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article view: 14

Article download: 7

IP Archives of Cytology and Histopathology Research


BCL2 expression in ductal carcinoma of breast and its association with other clinicopathologic variables


Full Text PDF Share on Facebook Share on Twitter


Research Article

Author Details : Sharmila G*, Praba V

Volume : 5, Issue : 1, Year : 2020

Article Page : 75-80


Suggest article by email

Abstract

Breast cancer has now become the most common cancer among Indian females exceeding cervical
cancer. Age adjusted incidence rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000
women. Trends of breast cancer now in India are increasing incidence at younger age group, late stage
of presentation, aggressive cancers in the young. Bcl 2-a protooncogene identified in 1984. The protein
is found mainly in the periphery of mitochondria, on the perinuclear membrane, and in the endoplasmic
reticulum. In our study bcl2 expression in different histologic types of breast carcinoma and correlates we
read about its expression with other clinico pathologic variables such as tumour size, histological grade,
lymph node status, hormone receptor status and Nottingham prognostic index. :In this study 23.3% (7
out of 30) of the cases showed positivity for bcl2 expression of which all cases were strongly positive.
Bcl2 expression was found in 45.5% grade I well differentiated ductal carcinoma,14.3% of Grade II
Moderately differentiated ductal carcinomas, all cases of mucinous carcinoma of breast(p-<0> and ER/PR status found to have a statistically significant direct correlation with p value<0> Bcl2 antagonism in these ER+ tumors might increase the effectiveness of these predominately proapoptotic
treatment even more than it does from combination with endocrine therapies. Further development of bcl2
inhibitors has been explored and small molecule inhibitors such as ABT-737 AND ABT-199 have been
recently introduced. Emerging evidence also suggests the usefulness of this type of theraphy in breast
cancer.

Keywords: Breast, Carcinoma, Bcl2, Apoptosis, BH3mimetics.

Doi : 10.18231/j.achr.2020.015

How to cite : Sharmila G, Praba V, BCL2 expression in ductal carcinoma of breast and its association with other clinicopathologic variables. IP Arch Cytol Histopathol Res 2020;5(1):75-80

Copyright © 2020 by author(s) and IP Arch Cytol Histopathol Res. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)